GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cantel Medical Corp (NYSE:CMD) » Definitions » EV-to-EBITDA

Cantel Medical (Cantel Medical) EV-to-EBITDA : 19.35 (As of May. 09, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Cantel Medical EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cantel Medical's enterprise value is $4,126 Mil. Cantel Medical's EBITDA for the trailing twelve months (TTM) ended in Apr. 2021 was $213 Mil. Therefore, Cantel Medical's EV-to-EBITDA for today is 19.35.

The historical rank and industry rank for Cantel Medical's EV-to-EBITDA or its related term are showing as below:

CMD' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.83   Med: 21.28   Max: 36.51
Current: 19.12

During the past 13 years, the highest EV-to-EBITDA of Cantel Medical was 36.51. The lowest was 6.83. And the median was 21.28.

CMD's EV-to-EBITDA is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 16.39 vs CMD: 19.12

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-09), Cantel Medical's stock price is $80.37. Cantel Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2021 was $1.256. Therefore, Cantel Medical's PE Ratio for today is 63.99.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Cantel Medical EV-to-EBITDA Historical Data

The historical data trend for Cantel Medical's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cantel Medical EV-to-EBITDA Chart

Cantel Medical Annual Data
Trend Jul11 Jul12 Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.02 21.85 24.62 31.42 22.98

Cantel Medical Quarterly Data
Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.14 22.98 16.70 20.69 20.47

Competitive Comparison of Cantel Medical's EV-to-EBITDA

For the Medical Instruments & Supplies subindustry, Cantel Medical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cantel Medical's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cantel Medical's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Cantel Medical's EV-to-EBITDA falls into.



Cantel Medical EV-to-EBITDA Calculation

Cantel Medical's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=4125.665/213.265
=19.35

Cantel Medical's current Enterprise Value is $4,126 Mil.
Cantel Medical's EBITDA for the trailing twelve months (TTM) ended in Apr. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $213 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cantel Medical  (NYSE:CMD) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Cantel Medical's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=80.37/1.256
=63.99

Cantel Medical's share price for today is $80.37.
Cantel Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.256.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Cantel Medical EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Cantel Medical's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Cantel Medical (Cantel Medical) Business Description

Traded in Other Exchanges
N/A
Address
150 Clove Road, 9th Floor, Little Falls, NJ, USA, 07424
Cantel Medical is a New Jersey-based manufacturer of hospital supplies for infection prevention, which include products used in endoscope disinfection, water purification systems for use in dialysis treatment, and dental supplies. The firm reports in four segments: medical (46% of fiscal 2020 sales), dental (32%), life sciences (19%), and dialysis (3%). Geographic exposure is primarily in the U.S., which accounts for about 75% of revenue, with international markets making up the remaining 25%.
Executives
Ann E Berman director 255 STATE STREET, BOSTON MA 02109
Jeffrey Z Mann officer: SVP, General Counsel 150 CLOVE ROAD, 9TH FLOOR, LITTLE FALLS NJ 07424
George L Fotiades director, officer: Chief Executive Officer 281 SUMMIT AVENUE, SUMMIT NJ 07901
Charles M Diker director, 10 percent owner, officer: Chairman ONE NEW YORK PLAZA, NEW YORK NY 10004
Shaun M. Blakeman officer: SVP - CFO C/O CANTEL MEDICAL CORP., 150 CLOVE ROAD, LITTLE FALLS NJ 07424
Jean Casner officer: SVP and CHRO 150 CLOVE ROAD, LITTLE FALLS NJ 07424
Brian Capone officer: SVP and Princ. Accounting Ofr 150 CLOVE ROAD, 9TH FLOOR, LITTLE FALLS NJ 07424
Peter G Clifford officer: President and COO 40 TOURNAMENT DRIVE SOUTH, HAWTHORN WOODS IL 60047
Seth M Yellin officer: Executive Vice President 150 CLOVE ROAD 9TH FLOOR LITTLE FALLS NJ 07424
Laura L Forese director 849 STONEWALL COURT FRANKLIN LAKES NJ 07417
Peter Pronovost director JHU-QSRG 1909 THAMES ST. - 2ND FLOOR BALTIMORE MD 21231
Anthony B Evnin director C/O VENROCK ASSOCIATES, 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Ronnie Myers director TOURO COLLEGE OF DENTAL MEDICINE 40 SUNSHINE COTTAGE ROAD VALHALLA NY 10595
Alan R Batkin director 399 PARK AVENUE, 10TH FLOOR, NEW YORK NY 10022
Karen Prange director 1108 S RIO VISTA BLVD, FORT LAUDERDALE FL 33316